semaglutide newtown square Weight Loss in PA Press Services Medical Weight Loss: Semaglutide &

As presented at the American Diabetes Association Meeting: this randomized phase 2b trial in 230 adults with overweight or obesity shows that aleniglipron, an oral small-molecule GLP1-RA, led to up to 11.3% body-weight loss compared with placebo after 36 weeks of treatment.

Find out if you qualify for this FDA-approved treatment and the benefits it offers for sustainable weight loss.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Lilly is counting on next-generation incretin medicines like Retatrutideas well as its oral GLP-1 Orforglipronto eventually pick up the torch from its current diabetes and obesity mainstays Mounjaro and Zepbound, both of which are underpinned by Lillys dual GIP/GLP-1 receptor agonist Tirzepatide.

Dual GIP/GLP-1 support with fewer side effects

Beyond GLP-1: The next wave of incretin-based obesity treatments GIP/GLP-1 dual agonists (e.g., #Tirzepatide) weight loss vs